Call Us: (1) 608 441-2729 - Email Us info@flugen.com
Twitter
M2SR: The Vaccine
Influenza
Leadership
Executive Team
Board of Directors
Clinical Advisory Board
Investors
News
Contact
Contact
Careers
News
News and opinions
FluGen’s M2SR Phase 2 Human Challenge Trial Initial Results
February 12, 2019
Maggie Coluccy
Influenza
Print Article
FluGen Topline Challenge Results Feb 2019
Download
Share this Story
Facebook
Twitter
LinkedIn
Reddit
Digg
Delicious
Google++
E-Mail+
Comments are closed.
Prev Post
Next Post
Recent News
UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine
Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice
FluGen’s M2SR Phase 2 Human Challenge Trial Initial Results
Flu shots urged as Madison’s FluGen plays role in effort for universal vaccine
FluGen completes dosing of phase 2 study to assess effectiveness of novel influenza vaccine designed to protect against mismatched strains
Twitter Widget
(c)2016 FluGen, Inc. All rights reserved.
Twitter
Back to Top
Enter your Infotext or Widgets here...
Comments are closed.